NOVO NORDISK A/S
Commented by Jens Castner on August 13th, 2026 | 08:00 CEST
Berkshire Hathaway, Novo Nordisk & Zefiro Methane: Do Good and Profit From It – Up to 250% Potential!
Berkshire Hathaway and Novo Nordisk have clearly exceeded expectations with their latest quarterly results. We take a closer look at these two heavyweights—and in the process, we also turn our attention to a small environmental services provider that, according to analysts, could offer significant potential for a tenfold return. Zefiro Methane embodies one of Warren Buffett's mottos particularly closely: do good and talk about it—or, even better, do good and make money from it.
Read
Commented by Fabian Lorenz on August 7th, 2026 | 07:20 CEST
Comeback Opportunity or Cause for Caution? Gerresheimer, Novo Nordisk, and American Atomics
Novo Nordisk shares have plummeted by about 10% in just a few trading days. This brings the pharmaceutical giant's rally, which began in April, to an end for the time being. Disappointing clinical trial results, combined with a smaller-than-expected increase to the company's full-year guidance, left investors underwhelmed. American Atomics, on the other hand, may represent a potential turnaround story. The company is working to establish an integrated value chain in the uranium sector. Given the global expansion targets for nuclear power plants, there can be little doubt that the company can expect strong demand for uranium. There are also hopes for a recovery at Gerresheimer. The sale of several business units has generated more than EUR 1 billion in proceeds for the struggling packaging specialist. Investors are now debating whether the transaction marks a genuine strategic turning point—or whether the company is simply selling valuable assets to address near-term financial challenges.
Read
Commented by André Will-Laudien on August 4th, 2026 | 09:10 CEST
"Buy the Dip" in the Life Sciences Supercycle: Gerresheimer, Vidac Pharma, Novo Nordisk, and Pfizer as Top Performers of the Future
Rising healthcare spending, an aging population, and an unprecedented depth of research are propelling the life sciences sector into a multi-year supercycle. And there are some strong players! Gerresheimer stands out as a brilliant infrastructure asset and a leading provider of high-quality primary packaging. In the field of injections and biologics, the company benefits directly from the explosion of complex therapies and GLP-1 markets. Vidac Pharma is conducting research in the field of cancer and leveraging the Warburg effect for its upcoming studies—a classic high-beta play for investors betting on above-average growth. Novo Nordisk remains the undisputed flagship of the obesity and diabetes wave, and Pfizer is using the current lull in valuations as an opportunity to ignite the next phase of growth with a broad pipeline spanning oncology, vaccines, and new forms of therapy. Who belongs in the portfolio for the next life sciences boom?
Read
Commented by André Will-Laudien on July 29th, 2026 | 07:50 CEST
Active Ingredients, Acquisitions and Spin-offs: Will Bayer, Novo Nordisk, BioNxt, or Evotec Become Top M&A Targets?
After years of consolidation, investors are asking: Will things start looking up again? The global life sciences sector is facing another massive wave of consolidation in 2026 as established pharmaceutical giants and agile biotech pioneers realign their businesses. Market dynamics remain high, but unfortunately, both sides are being exploited. So far, it has been predominantly speculative investors who are capitalizing on the current volatility. Following drastic share price losses and ongoing restructuring, the struggling Hamburg-based biotech company Evotec is increasingly in the crosshairs of financially strong acquirers seeking to acquire high-calibre drug discovery platforms at a bargain price. At the same time, BioNxt is attracting investor interest with its groundbreaking drug delivery systems and advanced clinical pipelines. Meanwhile, the market continues to speculate feverishly about a possible breakup or spin-off of individual divisions at the DAX-listed Bayer Group, which would massively increase its appeal to strategic buyers. On the other hand, Danish industry leader Novo Nordisk, driven by the sustained billion-dollar profits from its weight-loss portfolio, is acting as a financially powerful hunter in search of strategic acquisitions in the obesity and cardiovascular segments. For investors, this highly dynamic environment offers a rare opportunity to bet early on the year's hottest takeover candidates. What is the current status?
Read
Commented by Armin Schulz on July 29th, 2026 | 07:40 CEST
Billion-Dollar Markets of Obesity, Oncology, and Neurology in Focus: Novo Nordisk, Vidac Pharma, and AbbVie
The healthcare industry of the future is driven by three major megatrends: obesity, oncology, and neurology. While the market for cancer drugs is heading toward nearly USD 700 billion and Alzheimer's therapies are booming, the GLP-1 boom has only just begun and has replaced oncology as the largest driver of pipeline value. But not every company will benefit equally from this momentum. The key difference lies in strategic focus and the ability to translate scientific milestones into market success. We take a look at three companies today—Novo Nordisk, Vidac Pharma, and AbbVie—each of which embodies one of these areas.
Read
Commented by Nico Popp on July 23rd, 2026 | 07:50 CEST
Panic in the Multi-Billion-Dollar Market: Novo Nordisk and Halozyme Therapeutics Face Headwinds—BioNxt Solutions Nears a Turning Point
The global pharmaceutical market is worth hundreds of billions of dollars. Yet one of the industry's most surprising realities is that success increasingly depends not only on the active ingredient itself but also on how it is delivered. This does not refer to the cardboard box, but to the dosage form. Whenever patents expire, and blockbuster drugs face competition, innovative biotech companies seize the opportunity. New drug delivery technologies can transform well-known substances into more effective medicines, reduce side effects, and open up entirely new treatment options for patients. While established pharmaceutical giants spend vast sums defending market exclusivity, agile second-tier biotech companies are driving innovation through next-generation drug delivery platforms.
Read
Commented by Fabian Lorenz on July 14th, 2026 | 07:00 CEST
Bayer and Novo Nordisk Celebrate a Comeback! Is BioNxt Solutions Next?
With its GLP-1 therapy in tablet form, Novo Nordisk has returned to success on the stock market. Since April, the Danish pharmaceutical company's stock has risen by nearly 50% to around EUR 43. New research results are now being presented. Bayer has also recently celebrated a comeback on the stock market. Following the landmark glyphosate ruling by the US Supreme Court, hopes are growing that the company will be able to focus more strongly on its core business again in the future. To that end, the Leverkusen-based company has secured EUR 3 billion. BioNxt Solutions could be poised for a comeback. The biotech company's stock has nearly halved in value this year. Yet the news flow is positive and points to rising prices.
Read
Commented by Armin Schulz on July 9th, 2026 | 07:35 CEST
From Injection Blockbusters to an Oral Future: An Analysis of Novo Nordisk, BioNxt Solutions, and Pfizer in This Race
The weight-loss injection has fundamentally transformed the pharmaceutical industry and set in motion a business with billion-dollar potential, but this initial gold rush is over. The industry is undergoing a disruptive transformation in which more convenient oral alternatives are increasingly replacing the unpleasant injection. This development is shifting the balance of power, giving latecomers a historic opportunity while the market leaders must defend their dominance. The battle for power in obesity treatment has begun anew. Which company will take the lead in the next phase? Today, we take a closer look at Novo Nordisk, BioNxt Solutions, and Pfizer.
Read
Commented by Fabian Lorenz on July 2nd, 2026 | 07:25 CEST
Caution Advised with Novo Nordisk! TUI Is Making a Comeback! Globex Mining Outperforms Barrick Mining!
Caution advised with Novo Nordisk! Analysts warn that the pharmaceutical giant is heading toward a patent cliff. As a result, the company could lose billions. Without much fanfare, the stock has gained 30% in recent weeks. What do analysts say? Analysts remain bullish on TUI. The tourism group's stock is recommended as a "Buy". The easing of tensions in the Middle East and falling oil prices are fueling positive sentiment. The summer season will now be decisive. Globex Mining's stock has outperformed Barrick Mining this year. The recent correction offers an attractive entry opportunity to benefit from the commodities boom while diversifying risk.
Read
Commented by André Will-Laudien on June 29th, 2026 | 07:30 CEST
AI and M&A Frenzy in the Life Sciences Sector: Bayer, Vidac Pharma, Novo Nordisk, Evotec, and Eli Lilly
Yes, you read that correctly. Pharmaceutical companies are actively embracing artificial intelligence (AI) and, thanks to lower costs, better validation, and faster study setups, could emerge as winners of the new AI wave in the medium term. Many stocks in the life sciences sector had been overlooked by the market, but investors are now taking notice again. Eli Lilly is betting on AI and expanding its portfolio through targeted acquisitions, including the takeovers of sleep-wake specialist Centessa Pharmaceuticals and blood cancer specialist Ajax. At Evotec and Vidac Pharma, much of the focus is on cancer, while Novo Nordisk faces stiff competition from Eli Lilly's weight-loss drugs. Then came the welcome news regarding Bayer. The Supreme Court ruled that approximately 181,000 individual lawsuits alleging a lack of warning labels on packaging are no longer legally viable, as the US Environmental Protection Agency (EPA) has classified the herbicide glyphosate as safe. Lots of good news, and plenty of opportunities for active investors - we provide a few insights.
Read